Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated
chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible
for other Gilead-sponsored studies.